Summary
perts aimed to include non-europeans while avoiding those who work extensively with the cosmetic industry or who were involved in the generation of the report 1 . the expansion of views was meant to broaden and consolidate the basis for planning for future research opportunities. It is important to note that this is not a consensus report but reflects a spectrum of individual views and recommendations. the individual reviewers do not represent any institutions for the purpose of this review. the originators of the different comments are not identified, because each and every contribution was part of a general brainstorming process that lay the ground for further steps. Note that CAAt staff members were not involved in these comments, other than moderating the process and compiling the individual reviews. Further steps to promote a roadmap for research into alternatives for systemic endpoints will include strategic workshops based on currently commissioned white papers.
General assessment of the report
the general judgment on the report was very positive, as shown by some pertinent remarks: (european Commission, 2003) of the cosmetics legislation (Cosmetics Directive 76/768/eeC) provided inter alia for more detailed provisions on the phasing out of animal testing. this recently was transformed into a regulation (european Commission, 2009), which did not, however, affect these provisions: A general testing ban on cosmetic ingredients from 11 March 2009, reinforced for 10 animal test requirements by an instant marketing ban, as well as a marketing ban for the more complex endpoints (those requiring repeated substance application, e.g., repeated dose toxicity, sensitization, reproductive toxicity, carcinogenicity and toxicokinetics), to go into effect 11 March 2013. It is important to note here that the legislation provides for a review in 2011 of the feasibility of the 2013 deadline, and it can be further postponed in a co-decision procedure.
to support this process, a large eU expert consortium recently reviewed the current state of the art concerning alternative methods for cosmetics testing (Adler et al., 2011) . the review includes five toxicological key areas: toxicokinetics, skin sensitization, repeated dose toxicity, carcinogenicity, and reproductive toxicity. Based on a detailed analysis of the state of the art, the consortium estimates that full replacement of animal testing is possible for aspects of skin sensitization and toxicokinetics in approximately five to nine years, but more than 10 years will be required for the others. these time frames do not include formal validation and acceptance, i.e., a multi-year process.
the 7 th amendment and the resulting engagement of the cosmetic industry has become an engine for progress in the field of alternative methods over the last few years. However, this has a potential influence on other economic areas in the world and on other industrial fields as well. As one of our US reviewers
noted: "The EU Cosmetics Directive ban on animal testing for cosmetic ingredients is of major significance for chemical safety testing, as it fundamentally challenges animal-based testing practices, which have been in place for decades. The impact of the EU Cosmetics Directive is already being felt in sectors well beyond cosmetics, with the 2013 proposed ban looming large across the industry and regulatory agencies. On a sociopolitical level, the Directive represents a clash between society's wish for an end to animal testing on products such as cosmetics and the current state of science surrounding alternatives to animal testing."
In a similar way, the status of alternatives had been assessed, under the lead of eCVAM, after the 7 th amendment was issued (eskes and Zuang, 2005) . Such stocktaking can and must also be the starting point for the initiation or reshaping of activities (Hartung et al., 2003; Zuang and Hartung, 2005; Hartung, 2008) . the Centers for Alternative to Animal testing (CAAt) on both sides of the Atlantic hope that this will result in a new roadmap for scientific activities to further the replacement of animal testing. As a first step, the expert report was subjected to an independent review, presented here. the selection of ex- Adler et al. (2011) (Peyret et al., 2010 (Gerberick et al., 2007 (Sakaguchi et al., 2009 ). In our work using THP-1 and IL-8 release to identify sensitizers (Mitjans et al., 2010) (Natsch and Emter, 2008; Emter et al., 2010) (Nguyen et al., 1996; Sarrab et al., 2011; Delarue et al., 1991) . In addition, fairly well established culture models for primary human glomerular endothelial cells exist, which potentially could be used for repeat dose toxicity testing (Aydin et al., 2008 Carfi' et al., 2007 and not Carfi' et al., 2010 . Furthermore, several relevant reviews that specifically address in vitro immunotoxicity are not even mentioned, i.e. Galbiati et al., 2010; Corsini and Roggen, 2009; Lankveld et al., 2010 ." (Gennari et al., 2005) (Ringerike et al., 2005) . Although further refinement of this system is required, this assay holds promise for in vitro screening of chemicals for their immunotoxicity." -"The human whole blood cell culture, introduced more than 20 years ago, may also be useful in studying the biological effects of potential immunomodulatory chemicals based on immune cell activation and cytokine secretion (Langezaal et al., 2001 (Langezaal et al., , 2002 ." -"Cytokine production, together with lymphocyte proliferation, is currently in a pre-validation phase (Carfi' et al., 2007) .
Do you agree with the conclusions for the area? If not, where do you disagree? -"The conclusion is clear and easy to understand: 'in isolation, non-animal tests for hazard identification will not be sufficient to replace fully the need for animal testing for this endpoint, although they might reduce the overall need.' Again, this area would benefit from more details (or a summary) on what exactly is missing, how these gaps can be bridged, what a tiered safety assessment strategy (decision tree) -beyond the one-to-one replacement of animal studies -might look like, and how this can be achieved by 2019." -"I agree with the idea that potency prediction is lacking without animal testing. I am not convinced that the existing panel of predictive tests will provide a robust toolbox for hazard identification to distinguish between sensitizers and non-sensitizers with in vitro tests. I also agree with the idea of the need for a toolbox approach, with multiple endpoints that address numerous steps in the sensitization cascade. It is optimistic, perhaps overly optimistic, to estimate that the elimination of animal testing and hazard identification can be completed in the absence of animal data by 2017-2019. It is my opinion that the existing toolbox needs to be expanded and refined to the molecular level. Much more work related to the molecular pathways of ACD is necessary to develop novel tools. These new assays will need time for development." -"I also advise the authors to recognize that complete prediction of safety will never be possible for human use products. The existing predictions do not recognize the misuse/abuse of commercially available prescription and non-prescription products, as well as the use of products correctly but in the setting of co-morbid conditions that produce skin inflammation (leg ulcers, skin infections, underlying skin diseases such as atopic dermatitis, psoriasis, etc). Such human conditions subvert the model systems that may rely on assumptions such as steady-state health (and associated lack of inflammation), which is not always the situation in the above-described conditions." -"Did the authors anticipate the possibility that tests
Further
Based on results of two previous studies, the human T cell activation assay was selected as the most promising of the investigated in vitro immunotoxicity test. This assay is based on CD3/CD28-mediated T cell activation using proliferation and cytokine release (TNF-α and IFN-γ) as read-out parameters. Statistical analyses revealed that the human T cell activation test had a 'sensitivity' (correct prediction of immunosuppressive chemicals) of 76% and a 'specificity' (correct prediction of non-immunosuppressive chemicals) of 83% (manuscript in preparation). The human T cell activation assay may be a promising candidate for in vitro evaluation of immunosuppressive activity." -"Immunotoxicogenomics represents a novel approach to in-
vestigate immunotoxicity. Hochstenbach et al. (2010) Pfuhler et al., 2009) ." -P. 446, 2 nd paragraph: "Add Hayashi et al. (2005 ) in (e.g., Matthews et al., 2008 (Martin et al., 2009b) and prenatal developmental toxicity studies in rats and rabbits (Knudsen et al., 2009 , blood vessel development (Kleinstreuer et al., 2011) and prenatal developmental toxicity (Sipes et al., 2011 Yu et al. (2009 Yu et al. ( , 2010 Yu et al. ( , 2011 ." -"Missing important papers related to … work developed by the ReProTect program related to the human placental transport studies, also discussing these studies as supplementary to other studies and beneficial by providing human data Myllynen et al., 2010) ." -"Additional references on the concordance of WEC and other assays using transcriptomics can be identified in several other papers by Robinson et al. (2011) 
Overall Conclusions
this independent review endorses to a large extent the conclusions of the Adler et al. (2011) report. the addition of non-european experts and further independent experts added a number of approaches that were missing or not sufficiently addressed. This does not affect the assessment of the status of the different areas with regard to full replacement of animal tests; it does, however, broaden the basis of methods and approaches to be considered for a roadmap for future research and development. the provenance of reviewers from different parts of the world did not lead to evident differences in view with two exceptions: Non-europeans tended to recommend refinement and reduction methods, i.e. better animal tests, which do not represent an option in the eU cosmetics legislation. Stronger reference was made to the pathway-based approaches that dominate the US discussion.
Although there is general agreement on the time frames for complete replacement, there are also many methods that are just about ready for use and are being used to collect data and to evaluate the completeness of possible replacement (e.g., sensitization and toxicokinetics). Some of these methods may clear the current barriers in a time frame considerably shorter than 5 to 7 years. this does not include formal validation and acceptance, but it does represent a realistic view of the use of these for decision-making.
throughout, it was noted that this important stocktaking must be furthered now to strategic planning and a roadmap. Both the original report and this review acknowledge the progress made in all areas discussed here. the lack of full replacements at this point is not a reflection of the efforts spent but rather of the sheer size of the challenge and the time science needs to develop new approaches and undergo transition. If we do not lessen these efforts, and follow the many suggestions to a more strategic combination of assays and further development of the methods that are almost there, the ultimate goal of animal-free testing of cosmetic ingredients can become a reality.
